fullscreen

eFinder

eFinder

Home › Article

This biotech firm has room to run, even as its drug royalties are set to shrink

Cnbc · · 317 words · By Liz Napolitano
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about This biotech firm has room to run, even as its drug royalties are set to shrink

Biogen could continue to notch growth, even as the biotechnology firm prepares to see lower royalties tied to one of its popular drugs, according to Piper Sandler.

Claims checked 8
Techniques found 0
Topics 0

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center75%
Right25%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Biogen could continue to notch growth, even as the biotechnology firm prepares to see lower royalties tied to one of its popular drugs, according to Piper Sandler.

Why it matters

The investment firm upgraded Biogen to overweight from neutral.

Common ground

It also raised its price target to $214 from $177, implying 21% upside from Monday's close.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

open_in_new Read the original article: https://www.cnbc.com/2026/04/14/this-biotech-firm-has-room-to-run-even-as-its-dr…

fact_checkClaims Checked

eFinder analyzed this article and checked 8 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 4
info Single Source 2
cancel Disputed 1
help Insufficient Evidence 1
info
Claim 1: “the company's current enterprise value to current year EBITDA estimate ratio of roughly 11x”
SINGLE SOURCE
The provided evidence explains what EV/EBITDA is (Wikipedia) but does not provide the specific ratio for Biogen.
travel_explore
web search NEUTRAL — Enterprise value/EBITDA (more commonly referred to by the acronym EV/EBITDA) is a popular valuation multiple used to determine the fair market value of a company. By contrast to the more widely availa…
https://en.wikipedia.org/wiki/EV/EBITDA
travel_explore
web search NEUTRAL — EV/EBITDA (Enterprise value/Earnings before Interest, Taxes, Depreciation and Amortization) - представляет собой отношение стоимости компании (Enterprise Value, EV) к полученной ею прибыли до уплаты н…
https://finrange.com/ru/journal/post/evebitda
travel_explore
web search NEUTRAL — О сервисе Прессе Авторские права Связаться с нами Авторам Рекламодателям...
https://www.youtube.com/watch?v=FeiAN0O3ufg
cancel
Claim 2: “Shares are flat since the beginning of the year”
DISPUTED
Some sources mention shares falling or sliding due to guidance cuts, while another source states shares gained 28.89% over the past 52 weeks as of March 2026, making the 'flat' claim contradictory to the growth data.
travel_explore
web search NEUTRAL — Biogen Inc. (NASDAQ:BIIB) shares fell 2.6% on Thursday after the biotechnology company trimmed its full-year earnings forecast, overshadowing an otherwise strong third-quarter earnings beat that toppe…
https://investorshub.advfn.com/market-news/article/18784/bio…
travel_explore
web search NEUTRAL — Despite this strong performance, Biogen lowered its full-year adjusted EPS guidance to $14.50-$15.00, below the consensus estimate of $15.76, primarily due to anticipated costs from business developme…
https://www.investing.com/news/earnings/biogen-shares-slide-…
travel_explore
web search NEUTRAL — Biogen has been trailing the IBB since the middle part of the year when the stock completely fell apart in July.Both the IBB and Biogen started to drift lower till late September as shown in the chart…
https://seekingalpha.com/article/3787816-biogen-shares-have-…
info
Claim 3: “Of the 37 analysts covering Biogen, 15 have a buy or strong buy on the stock, according to LSEG data.”
SINGLE SOURCE
The search results for this claim only returned dictionary definitions of the word 'according' and did not provide any LSEG data or analyst counts for Biogen.
travel_explore
web search NEUTRAL — ACCORDING definition: agreeing. See examples of according used in a sentence.
https://www.dictionary.com/browse/according
travel_explore
web search NEUTRAL — ACCORDING meaning: 1. present participle of accord 2. to treat someone specially, usually by showing respect: . Learn more.
https://dictionary.cambridge.org/us/dictionary/english/accor…
travel_explore
web search NEUTRAL — Define according. according synonyms, according pronunciation, according translation, English dictionary definition of according. v. ac·cord·ed , ac·cord·ing , ac·cords v. tr. 1. To give or grant, esp…
https://www.thefreedictionary.com/according
check_circle
Claim 4: “Its [Ocrevus] patent exclusivity is due to expire between 2028 and 2029”
CORROBORATED
Three independent sources confirm that Ocrevus patent exclusivity expires between 2028 and 2029 (specifically 2028 in Europe and 2029 in the US).
travel_explore
web search NEUTRAL — 1. When will patent expiry impact OCREVUS’s sales? Patent expiration is expected around 2029–2030, with biosimilar competition likely to influence pricing and market share.
https://www.drugpatentwatch.com/p/biologics/tradename/OCREVU…
travel_explore
web search NEUTRAL — While Kesimpta’s patent extends to 2035, Roche’s patent for Ocrevus expires between 2028 and 2029 in the US and Europe. This may invite biosimilars that could disrupt pricing and erode Kesimpta’s mark…
https://www.linkedin.com/pulse/why-stock-performance-doesnt-…
travel_explore
web search NEUTRAL — According to GlobalData, Ocrevus’ patents are set to expire in Europe in 2028 and in the U.S. in 2029, paving the way for potential biosimilars to enter the market.
https://biospectrumasia.com/analysis/26/25658/mitigating-pat…
help
Claim 5: “BIIB YTD mountain Biogen shares are flat in 2026.”
INSUFFICIENT EVIDENCE
The claim states shares are 'flat in 2026'. However, evidence from March 04, 2026, states that Biogen shares gained 28.89% over the past 52 weeks, which contradicts the claim that they are flat.
travel_explore
web search NEUTRAL — In Q1, Biogen revenue rose 2% year over year to $2.5 billion, while earnings per share (EPS) jumped 31% to $2.15. Much of the gain came from a 74% year-over-year rise in Leqembi sales to $168 million.…
https://www.fool.com/investing/2026/05/14/best-healthcare-st…
travel_explore
web search NEUTRAL — Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics and biosimilars, revenue has trended down, and the stock spent much of 2025…
https://www.thestreet.com/investing/stocks/goldman-sachs-rai…
travel_explore
web search NEUTRAL — On March 04, 2026, Biogen Inc. (NASDAQ:BIIB) stock closed at $189.94 per share. One-month return of Biogen Inc. (NASDAQ:BIIB) was 2.47%, and its shares gained 28.89% over the past 52 weeks. Biogen Inc…
https://finviz.com/news/330682/what-makes-biogen-biib-an-att…
check_circle
Claim 6: “It [Piper Sandler] also raised its price target to $214 from $177”
CORROBORATED
Two independent sources confirm the price target increase to $214 from $177. SmartTrader explicitly lists the transition '$177 → $214'.
travel_explore
web search NEUTRAL — Additionally, Piper Sandler increased its price target to $177 from $157, pointing to the growth of Biogen’s Alzheimer’s treatment, Leqembi.214.13M. AMD.
https://www.investing.com/news/analyst-ratings/goldman-sachs…
travel_explore
web search NEUTRAL — The average price target represents a 11.01% upside from the last price of $192.98. This chart shows the closing price for BIIB for the last year in relation to the current analyst high, average, and …
https://www.pricetargets.com/NASDAQ/BIIB/
travel_explore
web search NEUTRAL — Biogen (BIIB) Analyst: Piper Sandler upgrades to “OVERWEIGHT“ Previously: “NEUTRAL” Price Target: $177 → $214.
https://smarttrader.community/analyst-rating-updates/analyst…
check_circle
Claim 7: “The investment firm [Piper Sandler] upgraded Biogen to overweight from neutral.”
CORROBORATED
Two independent web sources confirm that Piper Sandler upgraded Biogen from 'Neutral' to 'Overweight'.
travel_explore
web search NEUTRAL — In 1963, Piper supported Betty Miller 's successful attempt to be the first female pilot to fly solo across the Pacific Ocean, during which she delivered a twin-engine Piper aircraft from Oakland, Cal…
https://en.m.wikipedia.org/wiki/Piper_Aircraft
travel_explore
web search NEUTRAL — Apr 17, 2026 · Piper Aircraft, Inc. is a manufacturer of general aviation aircraft, located at the Vero Beach Municipal Airport in Vero Beach, Florida.
https://www.piper.com/
travel_explore
web search NEUTRAL — Discover Piper in Oceanside, CA—your destination for CA cuisine crafted with locally sourced, seasonal ingredients. Savor breakfast, lunch, and dinner, alongside freshly baked pastries and a morning c…
https://www.piperoceanside.com/
check_circle
Claim 8: “Ocrevus, a multiple sclerosis drug co-developed by Biogen, is a significant source of royalty-based income for the biotech company.”
CORROBORATED
Multiple sources confirm Biogen receives royalties from Ocrevus, including a specific mention of $137 million in royalties in a Q3 earnings report and a general mention of the royalty deal with Roche.
travel_explore
web search NEUTRAL — Roche has a competitive drug, Ocrevus. Biogen receives royalties on the drug, but that’s unlikely to make up for other losses and decreasing prices. And Celgene has a potential competitor in ozanimod,…
https://www.biospace.com/why-even-spinraza-can-t-save-biogen…
travel_explore
web search NEUTRAL — Biogen and Roche have signed a royalty deal for an experimental lymphoma drug developed by the Swiss pharmaceutical company, the latest agreement in a longstanding collaboration between the two that’s…
https://www.biopharmadive.com/news/roche-biogen-bispecific-r…
travel_explore
web search NEUTRAL — Biogen’s multiple sclerosis (MS) revenues were $2.31 billion in the reporter quarter including approximately $137 million in royalties on the sales of Roche’s RHHBY MS drug, Ocrevus.
https://ca.finance.yahoo.com/news/biogen-biib-q3-earnings-sa…
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.